Stevanato Group to receive $95 million to expand vial production in the United States
Stevanato Group subsidiary OMPI of America Inc. has entered into an agreement to support the Biomedical Advanced Research and Development Authority (BARDA) pursuant to which BARDA has agreed to provide up to approximately $95 million to Stevanato Group.
Under the agreement, Stevanato Group has agreed to expand its planned manufacturing capacity in Fishers, Indiana, for both standard and EZ-Fill® vials.
BARDA’s financing is intended to strengthen domestic capabilities in the US for national defence readiness and preparedness programmes for current and future public health emergencies.
In addition, Stevanato Group has agreed to provide priority access to designated BARDA vaccine and drug development partners, when necessary.
Franco Moro, Chief Executive Officer of Stevanato Group, said, “We are honoured to have been selected by BARDA for this important investment which we believe will help fortify the US pharmaceutical supply chain to meet the demands for current and future public health emergencies. We believe this investment will rapidly accelerate and scale Stevanato Group’s capacity in Indiana and further expand our growth in this key strategic market.”
This project has been supported in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA).
Image: Stevanato Group EZ-fill Platform sees capacity expansion in US.
